primary and 406 (36%) were secondary in which the patient had one or more previous breast augmentation procedures. Silicone gel implants were utilized in 471 (65%) of the primary and 324 (80%) of the secondary procedures. Operative technique involved a circumvertical or inverted-T mastopexy in 77% (n= 871) and a bilateral mastopexy in 93% of patients. The overall reoperation rate was 14.9% (13.2% of primary and 16.6% of secondary procedures) over a mean followup period of 43 months (range 4 months to 121 months). Tissue related complications consisting of recurrent or persistent ptosis and poor scaring were most common at 6.2% (n= 71). Implant related complications requiring a revision were most commonly a result of the patient's desire to change implant size 3.1% (n=36) and capsular contracture Baker III/IV in 2.8% (n= 32). There were no cases of periprosthetic infection requiring explantation and no significant skin flap necrosis (> 2cm) or nipple areolar loss noted.
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CONCLUSION:
One-stage augmentation mastopexy can be safely performed with a reoperation rate that is significantly lower than when the procedure is staged. The effectiveness of this procedure is defined by a low complication rate, acceptable aesthetic results, and by minimizing the number of operations for the patient. With appropriate patient selection and operative technique, acceptable outcomes can be achieved safely and effectively. 
METHODS:
A commercially available in-situ ELISA was standardized and validated for patients with confirmed BIA-ALCL diagnosis with clinical isolates and a laboratory strain. A panel of five pathologically confirmed BIA-ALCL patients were screened by serum, plasma, and peri-prosthetic effusion specimens and compared against serum, plasma, and non-neoplastic delayed seromas in six healthy control patients. Statistical analysis demonstrated assay consistency and reliability.
RESULTS: BIA-ALCL serum specimens and all control specimens were tested at full concentration, 1:100, 1:250, 1:500 and 1:1000 serial dilutions. All BIA-ALCL effusions demonstrated CD30 ELISA detection at full and all serial concentrations. BIA-ALCL plasma specimens were weakly positive at full concentration and no activity with serial dilution. BI-ALCL serum specimens and all control specimens were negative at all concentrations.
CONCLUSION: This is the first study to demonstrate a viable alternative to CD30 immunohistochemistry for the screening of BIA-ALCL. A CD30 ELISA represents a novel low-cost screening test, which may be used to screen suspicious aspirations of delayed periprosthetic fluid collections in an office-based setting. This preliminary study demonstrates reliability and efficacy, however prospective testing in an expanded cohort will be required to establish sensitivity and specificity.
